Braf V600E mutation in melanoma: translational current scenario.
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.
['Guadarrama-Orozco|J A|JA|', 'Ortega-Gómez|A|A|', 'Ruiz-García|E B|EB|', 'Astudillo-de la Vega|H|H|', 'Meneses-García|A|A|', 'Lopez-Camarillo|C|C|']
D019008:Drug Resistance, Neoplasm D006801:Humans D008545:Melanoma D009154:Mutation D048493:Proto-Oncogene Proteins B-raf D057170:Translational Research, Biomedical
BRAF V600E Melanoma Inhibitor resistance